The age-dependent decline in ATF6 has led to the exploration of therapeutic approaches aimed at enhancing ATF6 activity in the aged, pathologic heart in hopes of improving proteostasis thereby enhancing cardiac myocyte contractility, and reducing the progression to heart failure characterized by the accumulation proteotoxic aggregates, fibrosis, and decreased cardiac compliance. The gene discussed is ATF6; the disease is heart failure.